Hallmarks of liver cancer: Therapeutic implications
Cell · 2026-04 · 189 (8) · 2490-2514
DOI: 10.1016/j.cell.2026.03.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell, 2026-04. Verfasst von Josep M Llovet und 8 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Liver Cancer Program, Divisions of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sina…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Cholangiocarcinoma. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS, European Regional Development Fund.
Abstract (Originalsprache)
The hallmarks of cancer, first proposed in 2000, have since provided a unified framework for understanding the complexity of carcinogenesis. This conceptual model has profoundly influenced the treatment landscape of primary liver cancer, which includes hepatocellular carcinoma (HCC, ∼85%) and intrahepatic cholangiocarcinoma (iCCA, 10%)-malignancies with high mortality. Key hallmarks exhibited by HCC include sustaining proliferative signaling, inducing or accessing vasculature, and avoiding immune detection. Over the past two decades, outcomes for patients with advanced HCC have significantly improved with immunotherapies. iCCA is characterized by hallmarks such as sustaining proliferative signaling, deregulating cellular metabolism, and avoiding immune detection. Unlike HCC, roughly 45% of iCCA harbor alterations amenable to precision oncology approaches, including fibroblast growth factor receptor 2 (FGFR2) fusions, isocitrate dehydrogenase 1 (IDH1) mutations, ERBB2 alterations, and BRAF mutations. In this review, we explore how this framework has reshaped liver cancer care and discuss the resulting breakthroughs in management and emerging directions that may further improve therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Mount Sinai Liver Cancer Program, Divisions of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Liver Cancer Translational Research Group, Liver…
- Liver Cancer Translational Research Group, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
- Tumor Microenvironment Plasticity and Heterogeneity Research Group, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- European Regional Development Fund
- Fondazione AIRC per la ricerca sul cancro ETS
- American Cancer Society
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Mayo Clinic
- Ministerio de Ciencia e Innovación
Zitieren
APA
Llovet, J. M., Pinyol, R., Affo, S., Yarchoan, M., Gores, G. J., Kelley, R. K., Lowe, S. W., Sia, D., & Villanueva, A. (2026). Hallmarks of liver cancer: Therapeutic implications. Cell, 189(8), 2490-2514. https://doi.org/10.1016/j.cell.2026.03.001
Vancouver
Llovet JM, Pinyol R, Affo S, Yarchoan M, Gores GJ, Kelley RK, et al. Hallmarks of liver cancer: Therapeutic implications. Cell. 2026;189(8):2490-2514. doi:10.1016/j.cell.2026.03.001
BibTeX
@article{Llovet2026,
author = {Llovet, Josep M and Pinyol, Roser and Affo, Silvia and Yarchoan, Mark and Gores, Gregory J and Kelley, Robin Kate and Lowe, Scott W and Sia, Daniela and Villanueva, Augusto},
title = {Hallmarks of liver cancer: Therapeutic implications},
journal = {Cell},
year = {2026},
volume = {189},
number = {8},
pages = {2490--2514},
doi = {10.1016/j.cell.2026.03.001}
}
EUVIMED